Skip to main content
TLPH
NASDAQ Life Sciences

Talphera Posts Q3 Loss, Seeks FDA Nod to Close NEPHRO Enrollment Early

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.03
Mkt Cap
$53.722M
52W Low
$0.687
52W High
$1.57
52W Position info
50% above low
Off High info
34% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TLPH sits 50% above its 52-week low of $0.687.

Summary

Talphera reported a $4.0 million Q3 net loss and $14.2 million in cash, and said it has asked the FDA to allow an early close of NEPHRO CRRT enrollment at December 31, 2026; peak sales for nafamostat are now estimated above $200 million.


Key Events · Earnings and Guidance · TLPH

  • FDA Briefing Filed for Early Enrollment Close

    Talphera has submitted a briefing document asking the FDA to allow NEPHRO CRRT enrollment to close as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled.

  • Enrollment Past 75% With 80%+ Power

    More than 75% of the planned 70 patients are enrolled, and the study already exceeds 80% statistical power for the primary endpoint — the basis for the early-close request.

  • Q3 Net Loss of $4.0 Million

    Net loss was $4.0 million, or $0.05 per share, versus $4.4 million, or $0.11 per share, in Q3 2025; combined R&D and SG&A rose to $4.1 million from $3.4 million.

  • Cash Falls to $14.2 Million

    Cash and investments stood at $14.2 million at September 30, 2026, down from $20.4 million at December 31, 2025, against a going-concern warning previously disclosed in the Q2 10-Q.


Analysis · TLPH · Life Sciences

Cash is the pressure point: Talphera burned $4.0 million in Q3 and ended September with $14.2 million in cash and investments, down from $20.4 million at year-end 2025. At the current spend rate that is roughly three to four quarters of runway, against a going-concern warning previously disclosed in the Q2 10-Q. The offsetting news is regulatory. Enrollment has passed 75% of the planned 70 patients and the study already carries over 80% statistical power, so the company has asked the FDA to let it stop enrolling as of December 31, 2026 even if it falls short of 70. Updated market research also lifted the nafamostat CRRT peak sales estimate above $200 million. Separately, the company flagged that it will file a new S-3 shelf to replace the one expiring November 30, 2026 — a routine step, but one that keeps the door open to raising the cash it needs to fund a PMA filing.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLPH was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.7M. The 52-week trading range was $0.69 to $1.57. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLPH - Latest Insights

TLPH
Nov 12, 2026, 5:11 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.02
Real-time Price: $0.9801 info
Change: -$0.0399 (-4%) info
Market Cap: $53.722M info
TLPH
Nov 12, 2026, 4:01 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.9801 info
Change: -$0.0549 (-5%) info
Market Cap: $53.722M info
TLPH
Aug 12, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $0.9801 info
Change: -$0.4199 (-30%) info
Market Cap: $53.722M info
TLPH
Aug 12, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.39
Real-time Price: $0.9801 info
Change: -$0.4099 (-29%) info
Market Cap: $53.722M info
TLPH
Jun 23, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.9801 info
Change: -$0.0399 (-4%) info
Market Cap: $53.722M info